(NASDAQ: AURA) Aura Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Aura Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast AURA's revenue for 2027 to be $1,388,379,162, with the lowest AURA revenue forecast at $1,388,379,162, and the highest AURA revenue forecast at $1,388,379,162. On average, 1 Wall Street analysts forecast AURA's revenue for 2028 to be $3,611,028,217, with the lowest AURA revenue forecast at $3,611,028,217, and the highest AURA revenue forecast at $3,611,028,217.
In 2029, AURA is forecast to generate $6,010,718,911 in revenue, with the lowest revenue forecast at $6,010,718,911 and the highest revenue forecast at $6,010,718,911.